By Mill Chart
Last update: Jan 25, 2024
Our stock screener has singled out GILEAD SCIENCES INC (NASDAQ:GILD) as a stellar value proposition. NASDAQ:GILD not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. We'll explore this further.
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:GILD, the assigned 7 reflects its valuation:
ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:GILD was assigned a score of 8 for profitability:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:GILD, the assigned 5 reflects its health status:
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NASDAQ:GILD has achieved a 4 out of 10:
Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.
Our latest full fundamental report of GILD contains the most current fundamental analsysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GILEAD SCIENCES INC
NASDAQ:GILD (4/23/2024, 7:01:49 PM)
After market: 66.71 -0.32 (-0.48%)67.03
+0.08 (+0.12%)
Three of Wall Street's undervalued stocks could provide a unique blend of stability and long-term growth potential.
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Dividend stocks can be a smart way to ride out market volatility.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END